Approximately 6 months after removal of the pheochromocytoma, and ≈1.5 years after the initial episode, which anesthesia induction for elective surgery had evoked, the patient underwent the planned ...

A review of the literature and report of one institution's experience. Medicine (Baltimore) 1991; 70:46. Ulchaker, JC, Goldfarb, DA, Bravo, EL, Novick, AC. Successful outcomes in pheochromocytoma ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

A pheochromocytoma tumor ... went through with treatment for the tumor in October and suffered a setback post-surgery, but earlier today, she provided an uplifting update on her X account.

A few patients still have high blood pressure after surgery. Medicine may still be used for blood pressure control in those cases. Long-term follow-up care is of great value for everyone after ...

The most common complications associated with pheochromocytoma surgery include sustained hypertension and haemodynamic lability.14 As cardiac complications can occur with pheochromocytoma, it is ...

Chemotherapy/systemic therapy, radiotherapy, immunotherapy or surgery ≤ 21 days prior to registration ... number of prior chemotherapeutic or biologic therapies for malignant pheochromocytoma or ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

At the Baylor College of Medicine Endocrine Surgery Clinics, Drs ... hyperparathyroidism, adrenal masses, pheochromocytoma, Cushing’s syndrome and Conn’s syndrome. A new procedure allows surgeons, ...

Monitor HR during therapy. Bronchospastic disease. Pheochromocytoma. Surgery. Diabetes. May mask signs and increase risk for hypoglycemia. Hyperthyroidism. Avoid abrupt cessation. Hepatic impairment.